Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease virus, serotype 1, strain rn1250; live recombinant turkey herpesvirus, expressing the vp2 protein of infectious bursal disease virus, strain vhvt013-69 - immunologicals for aves, domestic fowl, avian herpes virus (marek's disease) + avian infectious bursal disease virus (gumboro disease) + newcastle disease virus/paramyxovirus - piletina - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus), and to prevent mortality, clinical signs and lesions caused by infectious bursal disease (ibd) virus.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunomodulatori za mačke, - mačke - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. pokusi imuniteta pokazani su tjedan dana nakon primarnog cijepljenja za rhinotracheitis, kalicivirus, chlamydophila felis i panleucopenia komponente. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europska Unija - hrvatski - EMA (European Medicines Agency)

corza medical gmbh - ljudskog fibrinogena, ljudskog trombina - hemostaza, kirurški - antihemorrhagics - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - live recombinant marek’s disease (md) virus, serotype 1, strain rn1250 - imunološki za aves - piletina - for active immunisation of one-day-old chicks to prevent mortality and clinical signs and reduce lesions caused by marek’s disease (md) virus (including very virulent md virus).

Europska Unija - hrvatski - EMA (European Medicines Agency)

elanco gmbh - spinozada - drugi ectoparasiticides za sistemsku primjenu - dogs; cats - liječenje i prevencija zaraze buha (ctenocephalides felis). preventivni učinak protiv ponovne infestacije rezultat je adulticidne aktivnosti i smanjenja proizvodnje jaja i traje do 4 tjedna nakon jednokratne primjene produkta. veterinarski medicinski proizvod može se koristiti kao dio strategije liječenja za kontrolu buha alergijskog dermatitisa (fad).

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ferring gmbh, wittland 11, kiel, njemačka - menotropin - prašak i otapalo za otopinu za injekciju - 1200 iu - urbroj: 1 bočica s praškom sadržava visokopročišćeni menotropin (humani menopauzni gonadotropin, hmg),što odgovara aktivnosti 1200 iu folikulostimulirajućeg hormona (fsh) i 1200 iu aktivnosti luteinizirajućeg hormona (lh). poslije rekonstitucije, 1 ml rekonstituirane otopine sadrži 600 iu visoko pročišćenog menotropina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ferring gmbh, wittland 11, kiel, njemačka - menotropin - prašak i otapalo za otopinu za injekciju - 600 iu - urbroj: 1 bočica s praškom sadržava visokopročišćeni menotropin (humani menopauzni gonadotropin, hmg) s 600 iuaktivnosti folikulostimulirajućeg hormona (fsh) i 600 iu aktivnosti luteinizirajućeg hormona (lh). poslije rekonstitucije, 1 ml rekonstituirane otopine sadrži 600 iu visoko pročišćenog menotropina

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ferring gmbh, wittland 11, kiel, njemačka - menotropin - prašak i otapalo za otopinu za injekciju - 75 iu - urbroj: jedna bočica praška sadrži visokopročišćeni menotropin (hmg), sa 75 iu aktivnosti folikulostimulacijskog hormona (fsh) i 75 iu aktivnosti luteinizacijskog hormona (lh).

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

hameln pharma gmbh, inselstrasse 1, hameln, njemačka - natrijev deksametazonfosfat - otopina za injekciju - urbroj: 1 ml otopine sadrži 4 mg deksametazonfosfata (u obliku natrijevog deksametazonfosfata) 2 ml otopine sadrži 8 mg deksametazonfosfata (u obliku natrijevog deksametazonfosfata)